Chinese biotech developing ADC and bispecific-antibody cancer drugs, including envafolimab, the first subcutaneous PD-L1 antibody.
Chinese biotech developing ADC and bispecific-antibody cancer drugs, including envafolimab, the first subcutaneous PD-L1 antibody.
Earns little from its own product sales; income comes mainly from partners that fund development and sell its drugs, through up-front fees, milestones and a share of sales. Envafolimab is commercialized in China by a partner, 3D Medicines, under a co-development deal.
Moat: narrow (IP / patents, process know-how). Proprietary bispecific/ADC platform and a first-in-class subcutaneous PD-L1 approval, but small commercial scale.
Headquarters: Suzhou, China · Founded: 2011 · Employees: 498
Size Alphamab Oncology (9966.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $666M, the 680th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$5.33 on 18 Nov 2026.
Performance Over six months the shares fell 37.8%, against -13.8% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 3rd lowest of 19 in its peer set.
Growth Revenue fell 31.8% over the last twelve months (peer median +18.4%); the operating margin is -37.8% (peer median -92.0%).
Valuation It trades at 24.0× forward earnings against a peer median of 20.8× (2nd most expensive of 5).
Capital Return on invested capital runs 47.6 points below its cost of capital (16.6% WACC).
Next results Next results expected around 30 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$579M | HK$614M | HK$694M | HK$242M | HK$194M |
| Revenue growth | — | -12% | +187% | +25% | — |
| Gross profit | HK$441M | HK$475M | HK$545M | HK$104M | HK$78.4M |
| EBITDA | -HK$146M | -HK$96.1M | HK$193M | -HK$281M | -HK$439M |
| Net income | -HK$194M | -HK$124M | HK$180M | -HK$233M | -HK$379M |
| Free cash flow | -HK$193M | -HK$136M | HK$270M | -HK$213M | -HK$478M |
| Capital expenditure | HK$17.7M | HK$34.3M | HK$23.6M | HK$40.0M | HK$151M |
| Total debt | n/a | HK$137M | HK$198M | HK$283M | HK$388M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alphamab Oncology 9966.HK | $666M | -38% | -32% | -38% | 24.0× | n/a |
| Akeso 9926.HK | $7.01B | -48% | +42% | -25% | n/a | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| RemeGen 9995.HK | $6.07B | -28% | +293% | 61% | 6.3× | -6.8% |
| Nanjing Leads Biolabs 9887.HK | $764M | -50% | n/a | -108% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 9966.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -24.6% | -7.0% | 3rd lowest of 21 |
| 6-month return | -37.8% | -13.8% | 3rd lowest of 19 |
| Distance from 52-week high | -56.4% | -44.5% | 5th lowest of 21 |
| Revenue growth (TTM) | -31.8% | +18.4% | lowest of 15 |
| Operating margin | -37.8% | -92.0% | 8th highest of 16 |
| Forward P/E | 24.0× | 20.8× | 2nd most expensive of 5 |
| ROIC minus cost of capital | -47.6 pp | -11.3 pp | 3rd lowest of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 24.0× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | n/a | 40.3% | +21.5% |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | n/a | n/a | n/a |
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | n/a | n/a | n/a |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | n/a | 44.8% | +14.7% |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 17.4× | n/a | n/a |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | n/a | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 19.2× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | n/a | -8.9% | -1.3% |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | n/a | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 37.9× | 17.3% | +11.8% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | n/a | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | n/a | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 22.3× | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | n/a | -13.5% | -10.9% |
| Aura Biosciences AURA | United States | $743M | -4% | n/a | n/a | n/a | n/a | n/a |